Transferrin‐bearing liposomes entrapping plumbagin for targeted cancer therapy
Authors:
Open Access
- 26 June 2019
- journal article
- research article
- Published by Wiley in Journal of Interdisciplinary Nanomedicine
- Vol. 4 (2) , 54-71
Abstract
The therapeutic potential of plumbagin, a naphthoquinone extracted from the officinal leadwort with anticancer properties, is hampered by its failure to specifically reach tumours at a therapeutic concentration after intravenous administration, without secondary effects on normal tissues. Its use in clinic is further limited by its poor aqueous solubility, its spontaneous sublimation, and its rapid elimination in vivo. We hypothesize that the entrapment of plumbagin within liposomes grafted with transferrin, whose receptors are overexpressed on many cancer cells, could result in a selective delivery to tumours after intravenous administration. The objectives of this study were therefore to prepare and characterize transferrin‐targeted liposomes entrapping plumbagin and to evaluate their therapeutic efficacy in vitro and in vivo. The entrapment of plumbagin in transferrin‐bearing liposomes led to an increase in plumbagin uptake by cancer cells and improved antiproliferative efficacy and apoptosis activity in B16‐F10, A431, and T98G cell lines compared with that observed with the drug solution. In vivo, the intravenous injection of transferrin‐bearing liposomes entrapping plumbagin led to tumour suppression for 10% of B16‐F10 tumours and tumour regression for a further 10% of the tumours. By contrast, all the tumours treated with plumbagin solution or left untreated were progressive. The animals did not show any signs of toxicity. Transferrin‐bearing liposomes entrapping plumbagin are therefore highly promising therapeutic systems that should be further optimized as a therapeutic tool for cancer treatment.Keywords
Funding Information
- Vivensa Foundation (R463/0216)
- Thammasat University (TU_9708)
- Worldwide Cancer Research (16‐1303)
This publication has 52 references indexed in Scilit:
- Systemic cancer therapy: achievements and challenges that lie aheadFrontiers in Pharmacology, 2013
- The transferrin receptor and the targeted delivery of therapeutic agents against cancerBiochimica et Biophysica Acta (BBA) - General Subjects, 2012
- Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplexBiomaterials, 2011
- Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administrationJournal of Controlled Release, 2011
- Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor‐2British Journal of Pharmacology, 2011
- Preparation, in vitro characterization, pharmacokinetic, and pharmacodynamic evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanomaDrug Delivery, 2010
- Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesiclesJournal of Controlled Release, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Measurement and pharmacokinetic study of plumbagin in a conscious freely moving rat using liquid chromatography/tandem mass spectrometryJournal of Chromatography B, 2006
- Niosomal Plumbagin with Reduced Toxicity and Improved Anticancer Activity in BALB/C MiceJournal of Pharmacy and Pharmacology, 1996